Do you want to read an article? Please log in or register.
Fecal calprotectin is a reliable marker of endoscopic response to vedolizumab therapy: A simple algorithm for clinical practice
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1
Inflamm Bowel Dis.
Reinisch W, Bressler B, Curtis R, Parikh A, Yang H, Rosario M, Røseth A, Danese S, Feagan B, Sands BE, Ginsburg P, Dassopoulos T, Lewis J, Xu J, Wyant T
doi: 10.1093/ibd/izy304.
COMMENTED
Gastrointestinal DiseasesInflammatory Bowel Disease
Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab
★ 3
Recommended and commented by
PD Dr Luc Biedermann, Faculty Member
Clin Gastroenterol Hepatol.
Hu A, Kotze PG, Burgevin A, Tan W, Jess A, Li PS, Kroeker K, Halloran B, Panaccione R, Peyrin-Biroulet L, Ma C, Ananthakrishnan AN
doi: 10.1016/j.cgh.2020.07.012.
Inflammatory Bowel Disease
Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors
Am J Gastroenterol.
Dulai PS, Battat R, Barsky M, Nguyen NH, Ma C, Narula N, Mosli M, Vande Casteele N, Boland BS, Prokop L, Murad MH, DʼHaens G, Feagan BG, Sandborn WJ, Jairath V, Singh S
doi: 10.14309/ajg.0000000000000596.
Inflammatory Bowel Disease
Immunological variables associated with clinical and endoscopic response to vedolizumab in patients with inflammatory bowel diseases
J Crohns Colitis.
Coletta M, Paroni M, Alvisi MF, De Luca M, Rulli E, Mazza S, Facciotti F, Lattanzi G, Strati F, Abrignani S, Fantini MC, Vecchi M, Geginat J, Caprioli F
doi: 10.1093/ecco-jcc/jjaa035.
Inflammatory Bowel Disease
Faecal Calprotectin Predicts Endoscopic and Histological Activity in Clinically Quiescent Ulcerative Colitis
J Crohns Colitis.
Hart L, Chavannes M, Kherad O, Maedler C, Mourad N, Marcus V, Afif W, Bitton A, Lakatos PL, Brassard P, Bessissow T
doi: 10.1093/ecco-jcc/jjz107.
COMMENTED
Inflammatory Bowel Disease
Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis
Inflamm Bowel Dis.
Battat R, Dulai PS, Vande Casteele N, Evans E, Hester KD, Webster E, Jain A, Proudfoot JA, Mairalles A, Neill J, Singh S, Chang JT, Rivera-Nieves J, Sandborn WJ, Boland BS
doi: 10.1093/ibd/izy307.
Esophagus Diseases
Heterogeneity in Clinical, Endoscopic, and Histologic Outcome Measures and Placebo Response Rates in Clinical Trials of Eosinophilic Esophagitis: A Systematic Review
Clin Gastroenterol Hepatol.
Ma C, van Rhijn BD, Jairath V, Nguyen TM, Parker CE, Aceves SS, Furuta GT, Gupta SK, Katzka DA, Safroneeva E, Schoepfer AM, Straumann A, Spergel JM, Pai RK, Feagan BG, Hirano I, Dellon ES, Bredenoord AJ
doi: 10.1016/j.cgh.2018.06.005.
Inflammatory Bowel Disease
Mucosal Biomarker of Innate Immune Activation Predicts Response to Vedolizumab in Crohn's Disease
Inflamm Bowel Dis.
Osterman MT, Gordon IO, Davis EM, Ciorba M, Glover SC, Abraham B, Khan F, Guo X, Yee EU, Allard FD, Claggett B, Shen B, Liu JJ
doi: 10.1093/ibd/izz222.
Inflammatory Bowel Disease
Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practice
Biologicals.
Ylisaukko-Oja T, Torvinen S, Aaltonen J, Nuutinen H, Blomster T, Jussila A, Pajala M, Salminen K, Moilanen V, Hakala K, Kellokumpu M, Toljamo K, Rautiainen H, Kuisma J, Peräaho M, Molander P, Silvennoinen J, Liukkonen V, Henricson H, Tillonen J, Esterinen M, Nielsen C, Hirsi E, Lääne M, Suhonen UM, Vihriälä I, Mäkelä P, Puhto M, Punkkinen J, Sulonen H, Herrala S, Jokelainen J, Tamminen K, Sipponen T
doi: 10.1016/j.biologicals.